ENVISIA THERAPEUTICS
As many as 285 million people suffer from disease-related visual impairments and blindness1, but an estimated 80 percent of these visual impairments are actually preventable2. Unfortunately, the safety and effectiveness of many medical therapies for ocular disorders are limited due to poor drug uptake, non-specificity to target tissues, systemic side effects, or poor adherence to therapy. With a rapidly aging population, the unmet medical needs in ocular disease are becoming even more pronounced. As a result, patients and physicians are seeking improved ocular therapeutics that can significantly enhance patient outcomes and convenience.
ENVISIA THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2013-01-01
Address:
Morrisville, North Carolina, United States
Country:
United States
Website Url:
http://www.envisiatherapeutics.com
Total Employee:
11+
Status:
Closed
Contact:
(919)973-1440
Email Addresses:
[email protected]
Total Funding:
46.1 M USD
Technology used in webpage:
SPF Amazon New Relic Amazon Ohio Region NameBright
Current Employees Featured
Founder
Investors List
Canaan Partners
Canaan Partners investment in Series A - Envisia Therapeutics
Morningside Group
Morningside Group investment in Series A - Envisia Therapeutics
Pappas Ventures
Pappas Ventures investment in Series A - Envisia Therapeutics
Wakefield Group
Wakefield Group investment in Series A - Envisia Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series A - Envisia Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2014-09-10 | LQ3 Pharmaceuticals | Envisia Therapeutics investment in Series A - LQ3 Pharmaceuticals | 10 M USD |
Official Site Inspections
http://www.envisiatherapeutics.com
- Host name: ec2-13-223-25-84.compute-1.amazonaws.com
- IP address: 13.223.25.84
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Envisia Therapeutics"
Envisia Therapeutics - Crunchbase Company Profile
When was the last funding round for Envisia Therapeutics? Envisia Therapeutics closed its last funding round on Mar 17, 2016 from a Series A round. Who are …See details»
Envisia Therapeutics 2025 Company Profile: Valuation, …
Envisia Therapeutics General Information Description. Developer of a bio-research platform intended to focus on the development of novel ocular …See details»
Company Information - RocketReach
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the …See details»
Envisia Therapeutics - VentureRadar
Caidya USA Privately Held Caidya is a global, mid-sized clinical research organization (CRO) dedicated to advancing healthcare innovation and partnering with biopharma sponsors to …See details»
Envisia Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Envisia Therapeutics Inc. of Durham, NC. Get the latest business insights from Dun & Bradstreet.See details»
Envisia Therapeutics - Craft
Envisia Therapeutics is a biotechnology company focused on the development of novel ocular therapies. It is leveraging the unique and powerful properties of the PRINT® platform to …See details»
Organization | Envisia Therapeutics
Envisia Therapeutics Report issue. For profit Phase 2. Founded: Morrisville NC United States ... Organization Overview. First Clinical Trial. 2015 NCT02371746. First Marketed Drug. None ...See details»
Envisia Therapeutics Inc - Company Profile and News
Company profile page for Envisia Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Envisia Therapeutics, Inc.:Company Profile & Technical Research ...
Envisia Therapeutics, Inc. is a company that provides Visual impairment, Pharmacy and Therapeutics, Drug uptake and more. Envisia Therapeutics, Inc. is headquartered in United …See details»
Envisia Therapeutics Company Profile -Sales, Contacts, …
Envisia Therapeutics is in the Pharmaceutical Preparations industry within the Chemicals and Allied Products sector and has been in business for approximately 12 years. The Most …See details»
Envisia Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore Envisia Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 16 news, Technology Platform:Monoclonal antibody, Drug:ENV-1305. ... The …See details»
Envisia Therapeutics - Funding, Financials, Valuation & Investors
Envisia Therapeutics has a post-money valuation in the range of $100M to $500M as of Mar 23, 2016, according to PrivCo. Sign up for a free trial to view exact valuation and search …See details»
Envisia Therapeutics, Inc. - third500.com
Envisia Therapeutics, formed by Liquidia Technologies, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and …See details»
Envisia Therapeutics Inc.
Envisia Therapeutics Inc. is betting that a proprietary method of engineering micro- and nanoparticles of precise size, shape, and chemistry will enable it to develop drugs for direct …See details»
Envisia Therapeutics - Pappas Capital
Envisia Therapeutics. ← Back to Ventures Portfolio. Envisia is a biotechnology company that licensed technology from Liquidia Technologies and is focused on the development of novel …See details»
Envisia Therapeutics Company Profile | Management and
Envisia Therapeutics Profile and History. Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the …See details»
Envisia Therapeutics | OIS@AAO | Ophthalmology Innovation Source
Envisia Therapeutics This company, founded as a spin-out of Liquidia Technologies in 2013, began with a $25 million Series A, with the goal of developing the PRINT particle platform for …See details»
Envisia Therapeutics | PPT - SlideShare
Feb 18, 2016 This document summarizes corporate milestones and pipeline for Envisia Therapeutics, a company developing ophthalmic drug delivery systems. Key points include: - …See details»
Envisia Therapeutics - Contacts, Employees, Board Members, …
Organization. Envisia Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. …See details»
IMPROVING OUTCOMES IN OPHTHALMOLOGY VIA SUSTAINED …
Envisia Therapeutics Dr Tomas Navratil Vice-President, Development Dr Benjamin Maynor Vice-President, Research Dr Benjamin Yerxa Chief Scientific Officer T: 919 973 1440 F: 919 973 …See details»